Patents by Inventor Kohei HAYASHIDA
Kohei HAYASHIDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11955302Abstract: An electromagnetic relay includes a fixed terminal, a movable contact piece, a first contact, and a second contact. The fixed terminal includes a first surface. The movable contact piece includes a second surface disposed to face the first surface. The first contact is embedded in one of the fixed terminal or the movable contact piece to be flush with one of the first surface or the second surface. The second contact is disposed on the other of the fixed terminal or the movable contact piece to face the first contact. The second contact protrudes from the other of the first surface or the second surface toward the first contact and include a contact surface smaller than the first contact when viewed from a direction facing the first contact.Type: GrantFiled: February 18, 2019Date of Patent: April 9, 2024Assignee: OMRON CORPORATIONInventors: Kohei Otsuka, Ryota Minowa, Hiroyuki Iwasaka, Yasuo Hayashida, Shingo Mori, Naoki Kawaguchi
-
Patent number: 11942297Abstract: A relay includes a movable contact piece having a movable contact, a fixed contact, a drive device configured to move the movable contact piece, a magnet to apply a Lorentz force to an arc in a first extension direction, a fixed terminal having an intermediate portion to apply a Lorentz force to the arc in a second extension direction, and a wall portion. The wall portion includes first and second wall surfaces. The first wall surface is disposed to face an arc-extinguishing space, and is disposed opposite to the movable contact and the fixed contact in the first extension direction. The second wall surface is disposed to face the arc-extinguishing space and is disposed downstream in the second extension direction with respect to the first wall surface. A distance from the movable contact piece to the second wall surface differs from a distance to the first wall surface.Type: GrantFiled: February 18, 2019Date of Patent: March 26, 2024Assignee: OMRON CORPORATIONInventors: Naoki Kawaguchi, Ryota Minowa, Yasuo Hayashida, Shingo Mori, Kohei Otsuka, Hiroyuki Iwasaka
-
Patent number: 11935716Abstract: A relay includes a fixed contact, a movable contact piece including a movable contact, a movable portion, a coil, a return spring, and a contact spring. The movable portion includes a drive shaft and a movable iron core. The drive shaft is fixed to the movable contact piece in a contact case and extends from an inside of the contact case to an outside of the contact case. The movable iron core is connected to the drive shaft outside the contact case. The return spring urges the movable portion in an open direction in which the movable contact is separated from the fixed contact. The contact spring urges the drive shaft in a contact direction in which the movable contact contacts the fixed contact. The contact spring is arranged outside the contact case.Type: GrantFiled: March 4, 2019Date of Patent: March 19, 2024Assignee: OMRON CORPORATIONInventors: Shingo Mori, Ryota Minowa, Yasuo Hayashida, Naoki Kawaguchi, Kohei Otsuka, Hiroyuki Iwasaka
-
Publication number: 20230159530Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: ApplicationFiled: January 9, 2023Publication date: May 25, 2023Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
-
Patent number: 11643411Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: GrantFiled: October 13, 2020Date of Patent: May 9, 2023Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
-
Publication number: 20230132191Abstract: A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid ? receptor agonist activity.Type: ApplicationFiled: December 15, 2022Publication date: April 27, 2023Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
-
Patent number: 11633392Abstract: The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid ? receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid ? receptor-related diseases (for example, headache) can be treated or prevented.Type: GrantFiled: September 15, 2017Date of Patent: April 25, 2023Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
-
Publication number: 20230087342Abstract: Provided are: an azepan derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof (in the formula: R1 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R2 and R3 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R4 and R5 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R6 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R7 and R8 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R9 and R10 are the same as or different from each other, and represent a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R11 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.Type: ApplicationFiled: September 29, 2020Publication date: March 23, 2023Inventors: Yoshikazu Watanabe, Daisuke Saito, Kohei Hayashida, Kohei Yamamoto, Mayu Namiki, Yuzo Mogi, Masahiro Yata
-
Publication number: 20220363667Abstract: To provide a novel T-type calcium channel blocker. A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker.Type: ApplicationFiled: July 17, 2019Publication date: November 17, 2022Inventors: Hiroto Tanaka, Isao Ooi, Daisuke Saito, Kohei Hayashida, Kohei Yamamoto, Atsufumi Kawabata
-
Publication number: 20220299357Abstract: A weighing apparatus includes: a transport unit capable of transporting an article; a weighing unit connected to the transport unit and configured to output an original signal related to a weight; and a weighing control unit configured to output a weighing value of the article by processing the original signal, wherein the weighing control unit is configured: to determine whether or not to adjust a zero point on the basis of a determination signal obtained by applying a first filter to the original signal; to generate an adjustment signal obtained by applying a second filter having more stages than the first filter to the original signal or the determination signal in a case where it is determined that the zero point is to be adjusted; and to perform adjustment of the zero point on the basis of the adjustment signal.Type: ApplicationFiled: March 16, 2022Publication date: September 22, 2022Applicant: Ishida Co., Ltd.Inventors: Yoshinori TARUMOTO, Shoko TAJIRI, Kohei HAYASHIDA
-
Publication number: 20220267327Abstract: Provided is, for example, a method for producing a morphinan derivative represented by General Formula (II), including the step of: allowing metal sodium and ethylenediamine to act on a morphinan derivative represented by General Formula (I) in presence of an auxiliary solvent. wherein R1 represents a hydrogen atom, or a C1-10 alkyl group, a C3-6 cycloalkyl group, a C2-6 alkenyl group, a C6-10 aryl group, or a heteroaryl group optionally having a substituent, R2 represents an amino protecting group, R3 represents a methoxy group, R4 and R5 represent a hydrogen atom or a hydroxy group, R6 and R7 represent a hydrogen atom or an electron-donating group, wherein R6 and R7 are not simultaneously a hydrogen atom, and X represents O or CH2.Type: ApplicationFiled: July 17, 2020Publication date: August 25, 2022Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Daisuke SAITO, Kohei HAYASHIDA
-
Publication number: 20220226299Abstract: A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.Type: ApplicationFiled: March 26, 2020Publication date: July 21, 2022Applicants: NIPPON CHEMIPHAR CO., LTD., UTI LIMITED PARTNERSHIP, KINKI UNIVERSITYInventors: Gerald W. ZAMPONI, Vinicius de Maria GADOTTI, Atsufumi KAWABATA, Toru OGAWA, Hiroto TANAKA, Isao OOI, Daisuke SAITO, Kohei HAYASHIDA, Kohei YAMAMOTO
-
Patent number: 11370761Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydrType: GrantFiled: January 22, 2018Date of Patent: June 28, 2022Assignees: Nippon Chemiphar Co., Ltd., Kinki UniversityInventors: Hiroto Tanaka, Isao Ooi, Kohei Hayashida, Toru Ogawa, Atsufumi Kawabata
-
Publication number: 20210371422Abstract: A compound represented by the following general formula (I), wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms and the alkylene moiety has 1 to 5 carbon atoms, or the like, R2 represents a 4- to 7-membered saturated heterocycle containing one or two heteroatoms which may be the same or different and are selected from N, O, and S, and two or more carbon atoms as ring-constituting atoms, the heterocycle may be substituted with a substituent such as an oxo group, R2 binds to Y via a carbon atom as a ring-constituting atom of R2, R3, R4, and R5, which are the same or different, represent hydrogen; hydroxy; or the like, R6a and R6b, which are the same or different, represent hydrogen or the like, R7 and R8, which are the same or different, represent hydrogen or the like, R9 and R10, which are the same or different, represent hydrogen or the like, X represents O or CH2, and Y represents C(?O) or the like), a tautomer of the compound, a stereoisomeType: ApplicationFiled: August 8, 2017Publication date: December 2, 2021Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
-
Publication number: 20210323930Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydrType: ApplicationFiled: January 22, 2018Publication date: October 21, 2021Inventors: Hiroto Tanaka, Isao Ooi, Kohei Hayashida, Toru Ogawa, Atsufumi Kawabata
-
Publication number: 20210040094Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R9 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: ApplicationFiled: October 13, 2020Publication date: February 11, 2021Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
-
Publication number: 20200079775Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and Rio, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: ApplicationFiled: July 19, 2019Publication date: March 12, 2020Applicant: NIPPON CHEMIPHAR CO., LTDInventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
-
Publication number: 20190328725Abstract: The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid ? receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid ? receptor related diseases (for example, headache) can be treated or prevented.Type: ApplicationFiled: September 15, 2017Publication date: October 31, 2019Applicant: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
-
Patent number: 10442802Abstract: A morphinan derivative represented by the following general formula (I): (wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc., R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group, Y binds to a carbon atom as a ring-constituting atom of R2, R3, R4, and R5 represent hydrogen; hydroxy, etc., R6a and R6b represent hydrogen, etc., R7 and R8 represent hydrogen, etc., R9 and R10, which are the same or different, represent hydrogen, etc., X represents O or CH2, and Y represents C(?O)), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: GrantFiled: March 17, 2016Date of Patent: October 15, 2019Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
-
Patent number: 10350645Abstract: An article rejecting system includes: a conveyance unit that conveys an article along a conveying direction; a detection unit that detects the article which is conveyed by the conveyance unit; a rejecting unit that is provided on a downstream side of the detection unit in the conveying direction and performs a rejecting motion for rejecting the article which is conveyed by the conveyance unit; a control unit that controls the rejecting unit such that the rejecting motion is performed at a predetermined automatic timing when the detection unit detects the article; and an input unit that accepts input of a manual operation for causing the rejecting unit to perform the rejecting motion at a manual timing. The control unit sets the automatic timing based on the manual timing, if the input unit accepts the input of the manual operation when the detection unit detects the article.Type: GrantFiled: February 23, 2018Date of Patent: July 16, 2019Assignee: ISHIDA CO., LTD.Inventors: Shoji Suda, Emi Mizuno, Ken Iwakawa, Kohei Hayashida, Yuzuru Yamada